Research Article
The Cost of Managing Type 2 Diabetes Mellitus in Greece: A Retrospective Analysis of 10-Year Patient Level Data “The HERCULES Study”
Table 3
Pharmaceutical treatment: antidiabetic and comorbidities therapies.
| | | Total ( = 211) | HbA1c ≤ 7 ( = 100) | HbA1c > 7 ( = 111) | value |
| | Number of antidiabetic agents | | | | | Mean
(SD) | 3.4
(1.5) | 3.1
(1.4) | 3.7
(1.5) | <0.01 | | Duration of antidiabetic therapy (years) | | | | | Mean
(SD) | 7.6
(3.8) | 7.1
(3.4) | 8.1
(4.1) | 0.375 | | Number of comorbidities treatments | | | | | Mean
(SD) | 5.5
(3.0) | 5.4
(3.2) | 5.6
(2.8) | 0.630 | | Antidiabetic agents () | | | | | | Alpha-glucosidase inhibitors | 22/211 (10.4%) | 15/111 (13.5%) | 7/100 (7.0%) | 0.187 | | Biguanides | 180/211 (85.3%) | 93/111 (83.8%) | 87/100 (87.0%) | 0.643 | | DPP4 inhibitors | 59/211 (28.0%) | 26/111 (23.4%) | 33/100 (33.0%) | 0.163 | | Glitazones | 39/211 (18.5%) | 23/111 (20.7%) | 16/100 (16.0%) | 0.481 | | GLP-1 analogues | 9/211 (4.3%) | 4/111 (3.6%) | 5/100 (5.0%) | 0.739 | | Long-acting insulin | 129/211 (61.1%) | 87/111 (78.4%) | 42/100 (42.0%) | <0.001 | | Rapid-acting insulin | 99/211 (46.9%) | 68/111 (61.3%) | 31/100 (31.0%) | <0.001 | | Meglitinides | 45/211 (21.3%) | 22/111 (19.8%) | 23/100 (23.0%) | 0.693 | | Sulphonylureas | 137/211 (64.9%) | 71/111 (64.0%) | 66/100 (66.0%) | 0.869 |
|
|
